MQS Management LLC Has $832,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

MQS Management LLC boosted its position in AstraZeneca PLC (NASDAQ:AZN) by 303.4% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 10,681 shares of the company’s stock after purchasing an additional 8,033 shares during the period. MQS Management LLC’s holdings in AstraZeneca were worth $832,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of AZN. Simmons Bank boosted its position in AstraZeneca by 7.3% during the third quarter. Simmons Bank now owns 39,074 shares of the company’s stock worth $3,044,000 after purchasing an additional 2,663 shares during the period. Dillon & Associates Inc. lifted its stake in shares of AstraZeneca by 27.1% during the 3rd quarter. Dillon & Associates Inc. now owns 32,850 shares of the company’s stock worth $2,562,000 after buying an additional 7,013 shares during the last quarter. Cumberland Partners Ltd boosted its holdings in shares of AstraZeneca by 5.6% during the 3rd quarter. Cumberland Partners Ltd now owns 4,398 shares of the company’s stock worth $343,000 after buying an additional 233 shares during the period. Aigen Investment Management LP acquired a new position in AstraZeneca in the 3rd quarter valued at about $308,000. Finally, Savvy Advisors Inc. acquired a new position in AstraZeneca in the 3rd quarter valued at about $211,000. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

AZN opened at $65.19 on Wednesday. The firm has a market cap of $202.13 billion, a P/E ratio of 31.49, a price-to-earnings-growth ratio of 1.20 and a beta of 0.47. The business’s fifty day moving average is $76.20 and its 200-day moving average is $78.47. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89.

Wall Street Analyst Weigh In

AZN has been the subject of a number of research analyst reports. TD Cowen boosted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.